IL2 and congenital rubella syndrome: To reduce both the toxicity of IL-2 and CRS, synthetic IL-2 receptor-beta (IL-2Rβ) and IL-2 pairs were developed to be used as an orthogonal system to increase the specificity and controllability of adoptive cell therapy.64–66